Stockscreener 앱 받기
51.00
1.35%
-0.70
시간 외 거래:
51.00
전일 마감가:
$51.70
열려 있는:
$52.38
하루 거래량:
437.40K
Relative Volume:
0.74
시가총액:
$1.52B
수익:
$232.39M
순이익/손실:
$-26.79M
주가수익비율:
-47.20
EPS:
-1.0804
순현금흐름:
$4.41M
1주 성능:
-7.61%
1개월 성능:
-12.63%
6개월 성능:
-22.01%
1년 성능:
+131.40%
1일 변동 폭
$50.80
$52.38
1주일 범위
$49.45
$56.04
52주 변동 폭
$20.79
$73.30
Anaptysbio Inc Stock (ANAB) Company Profile
명칭
Anaptysbio Inc
전화
858-362-6295
주소
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
51.00 | 1.52B | 232.39M | -26.79M | 4.41M | -1.0804 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-06-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-12-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-07-22 | 개시 | H.C. Wainwright | Buy |
| 2024-07-19 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-04-16 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Wells Fargo | Overweight |
| 2024-03-12 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-02-26 | 개시 | BTIG Research | Buy |
| 2024-02-21 | 개시 | Stifel | Buy |
| 2024-02-16 | 개시 | Piper Sandler | Overweight |
| 2023-05-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-05-18 | 개시 | TD Cowen | Outperform |
| 2023-01-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-09-13 | 다운그레이드 | Truist | Buy → Hold |
| 2022-09-01 | 개시 | Raymond James | Outperform |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-22 | 개시 | H.C. Wainwright | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-03-16 | 업그레이드 | Truist | Hold → Buy |
| 2021-03-09 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-03-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-02-11 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2020-10-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-10-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2019-11-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-11-08 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-20 | 개시 | H.C. Wainwright | Buy |
| 2018-11-21 | 개시 | JP Morgan | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-04-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | 재확인 | Stifel | Buy |
| 2018-03-06 | 재확인 | Stifel | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2018-01-23 | 재확인 | Credit Suisse | Outperform |
| 2017-11-15 | 개시 | SunTrust | Buy |
| 2017-11-09 | 개시 | Jefferies | Buy |
| 2017-10-11 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Anaptysbio Inc 주식(ANAB)의 최신 뉴스
AnaptysBio (ANAB) Is Down 7.6% After Tax-Driven Earnings Surge Masks Underlying Cash Performance - Yahoo Finance
AnaptysBio (NASDAQ:ANAB) Stock Bumped Up to Buy by Wall Street Zen - MarketBeat
AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns? - Insider Monkey
How Return To Profit Will Impact AnaptysBio (ANAB) Investors - simplywall.st
ANAB Reiterated by HC Wainwright & Co. -- Price Target Maintained at $95 - GuruFocus
Q3 Earnings Estimate for AnaptysBio Issued By HC Wainwright - MarketBeat
ANAB Maintained by Leerink Partners -- Price Target Lowered to $81 - GuruFocus
Leerink Partners Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat
Leerink Partners maintains Outperform rating on AnaptysBio, $81 price target - TradingView
AnaptysBio (ANAB) Flags Positive AZUR 1 Data With Approval And Legal Timelines - simplywall.st
Bank of America Corp DE Makes New $28.20 Million Investment in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
AnaptysBio earnings analysis: questions answered and next catalysts - Investing.com
AnaptysBio (NASDAQ:ANAB) Shares Down 6.2%What's Next? - MarketBeat
AnaptysBio, Inc. (0HFQ.L) latest press releases and corporate news - Yahoo Finance UK
AnaptysBio, Inc. (ANAB) Stock Price, News, Quote & History - Yahoo! Finance Canada
AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 524c - StreetInsider
Why is AnaptysBio stock rising afterhours today? - Investing.com
Why is AnaptysBio stock rising afterhours today? By Investing.com - Investing.com South Africa
AnaptysBio Net Income Jumps to $177.3 Million on $181.5 Million Tax Benefit - Minichart
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
AnaptysBio Inc (ANAB) Q2 Revenue Beats Estimates; Price-to-Sales Ratio Signals High Growth Expectations - GuruFocus
AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours - marketscreener.com
Anaptys Q2FY26 Results: Net profit jumps on $181.5m tax benefit - scanx.trade
AnaptysBio Q2 collaboration revenue rises on higher Jemperli royalties - TradingView
Spin-off leaves AnaptysBio (ANAB) a lean royalty firm - Stock Titan
Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update - Yahoo Finance
Anaptysbio Stock Price Forecast. Should You Buy ANAB? - StockInvest.us
AnaptysBio, Inc. (ANAB) Stock Analysis: Exploring A Potential 62.78% Upside - DirectorsTalk Interviews
AnaptysBio (ANAB) director adds shares as RSUs vest - Stock Titan
Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB) - Yahoo Finance
AnaptysBio earnings on deck: Jemperli lawsuit takes center stage By Investing.com - Investing.com Nigeria
AnaptysBio earnings on deck: Jemperli lawsuit takes center stage - investing.com
ANAB Q2'26 Earnings: EPS estimate is (0.47) USD - TradingView
Squarepoint Ops LLC Has $21.90 Million Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio, Inc. $ANAB Shares Purchased by Hsbc Holdings PLC - MarketBeat
U.S. Earnings Preview: After Market Close Sept. 8 - moomoo.com
Irenic Capital Management LP Makes New Investment in AnaptysBio, Inc. $ANAB - MarketBeat
Bank of New York Mellon Corp Makes New $3.81 Million Investment in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc. (ANAB) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
ANAB Q2'26 Earnings: revenue estimate is 8.89M USD - TradingView
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
U.S. Earnings Preview: After Market Close Sept. 1 - Moomoo
AnaptysBio stock rating maintained at Outperform by Wolfe Research - Investing.com Nigeria
AnaptysBio earnings on deck: Can Jemperli offset revenue slide? By Investing.com - Investing.com Australia
AnaptysBio earnings on deck: Can Jemperli offset revenue slide? - Investing.com
Empowered Funds LLC Makes New $13.91 Million Investment in AnaptysBio, Inc. $ANAB - MarketBeat
1,844,049 Shares in AnaptysBio, Inc. $ANAB Bought by BlackRock Inc. - marketbeat.com
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Palo Alto Investors LP Purchases Shares of 603,489 AnaptysBio, Inc. $ANAB - MarketBeat
Hsbc Holdings PLC Purchases Shares of 216,949 AnaptysBio, Inc. $ANAB - MarketBeat
Anaptysbio Inc (ANAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):